Overview Of Dendritic Cell Vaccines For Brain Tumors

Dc based immunotherapy is safe and can promote antitumor immune responses and prolonged survival of cancer patients.

Overview of dendritic cell vaccines for brain tumors.

Dc vaccine has been introduced as a new therapeutic strategy in cancer patients. However this treatment fails to show clinical benefit in many patients. Gliomas typically arise from two different cell types in the brain astrocytes or oligodendrocytes. Of the various forms of immunotherapy dendritic cell dc based therapies are well situated to be used to induce antitumor immunity given the specialized ability of dcs to both prime and or boost innate and adaptive immune responses.

It s made with tissue from each participant s brain tumor. Tumor cells however hijack the immune system causing t cell exhaustion and dc dysfunction. This is combined with dendritic immune cells from the person s blood. Dendritic cells dcs are powerful antigen presenting cells for the induction of antigen specific t cell response.

Dendritic cells guide the response of t cells to fight off invaders. Tumor induced t cell exhaustion may be reversed through immune checkpoint blockade icb. The vaccine is called dcvax l. Brain tumors are a diverse group of biologically and pathologically distinct intracranial neoplasms that include tumors of neuroepithelial tissue gliomas meningeal tumors and primary lymphomas of the central nervous system non gliomas see buckner et al 2007 for review.

Dendritic cells dcs are essential in immunity owing to their role in activating t cells thereby promoting antitumor responses. 4 clinical trials underway have demonstrated the successful application of dc vaccines to induce antitumor.